| Tyrosine kinase inhibition: an approach to drug development A Levitzki, A Gazit Science 267 (5205), 1782-1788, 1995 | 2154 | 1995 |
| Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells R Catlett-Falcone, TH Landowski, MM Oshiro, J Turkson, A Levitzki, ... Immunity 10 (1), 105-115, 1999 | 2122 | 1999 |
| Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor N Meydan, T Grunberger, H Dadi, M Shahar, E Arpaia, Z Lapidot, ... Nature 379 (6566), 645-648, 1996 | 1049 | 1996 |
| Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells R Garcia, TL Bowman, G Niu, H Yu, S Minton, CA Muro-Cacho, CE Cox, ... Oncogene 20 (20), 2499-2513, 2001 | 1006 | 2001 |
| EGF induces tyrosine phosphorylation of phospholipase C-II: a potential mechanism for EGF receptor signaling B Margolis, SG Rhee, S Felder, M Mervic, R Lyall, A Levitzki, A Ullrich, ... Cell 57 (7), 1101-1107, 1989 | 888 | 1989 |
| Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors A Gazit, P Yaish, C Gilon, A Levitzki Journal of medicinal chemistry 32 (10), 2344-2352, 1989 | 762 | 1989 |
| Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors P Yaish, A Gazit, C Gilon, A Levitzki Science 242 (4880), 933-935, 1988 | 751 | 1988 |
| ROS, stress‐activated kinases and stress signaling in cancer M Benhar, D Engelberg, A Levitzki EMBO reports, 2002 | 747 | 2002 |
| Transglutaminase is essential in receptor-mediated endocytosis of α2-macroglobulin and polypeptide hormones PJA Davies, DR Davies, A Levitzki, FR Maxfield, P Milhaud, ... Nature 283 (5743), 162-167, 1980 | 634 | 1980 |
| Negative cooperativity in regulatory enzymes A Levitzki, DE Koshland Jr Proceedings of the National Academy of Sciences 62 (4), 1121-1128, 1969 | 580 | 1969 |
| Crystal structure of Hck in complex with a Src family–selective tyrosine kinase inhibitor T Schindler, F Sicheri, A Pico, A Gazit, A Levitzki, J Kuriyan Molecular cell 3 (5), 639-648, 1999 | 550 | 1999 |
| Mode of coupling between the β-adrenergic receptor and adenylate cyclase in turkey erythrocytes AM Tolkovsky, A Levitzki Biochemistry 17 (18), 3795-3810, 1978 | 483 | 1978 |
| Flk-1 as a target for tumor growth inhibition LM Strawn, G McMahon, H App, R Schreck, WR Kuchler, MP Longhi, ... Cancer Research 56 (15), 3540-3545, 1996 | 451 | 1996 |
| Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3 … M Nagane, A Levitzki, A Gazit, WK Cavenee, HJS Huang Proceedings of the National Academy of Sciences 95 (10), 5724-5729, 1998 | 442 | 1998 |
| Prevention of lipopolysaccharide-induced lethal toxicity by tyrosine kinase inhibitors A Novogrodsky, A Vanichkin, M Patya, A Gazit, N Osherov, A Levitzki Science 264 (5163), 1319-1322, 1994 | 402 | 1994 |
| Tyrphostins: tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction A Levitzki The FASEB journal 6 (14), 3275-3282, 1992 | 400 | 1992 |
| Enhanced ROS production in oncogenically transformed cells potentiates c-Jun N-terminal kinase and p38 mitogen-activated protein kinase activation and sensitization to … M Benhar, I Dalyot, D Engelberg, A Levitzki Molecular and cellular biology 21 (20), 6913-6926, 2001 | 383 | 2001 |
| Epidermal‐growth‐factor‐dependent activation of the src‐family kinases N Osherov, A Levitzki European journal of biochemistry 225 (3), 1047-1053, 1994 | 374 | 1994 |
| The effect of tyrosine‐specific protein phosphorylation on the assembly of adherens‐type junctions. T Volberg, Y Zick, R Dror, I Sabanay, C Gilon, A Levitzki, B Geiger The EMBO journal 11 (5), 1733-1742, 1992 | 373 | 1992 |
| From epinephrine to cyclic AMP A Levitzki Science 241 (4867), 800-806, 1988 | 362 | 1988 |
